WallStreetZenWallStreetZen

NASDAQ: XENE
Xenon Pharmaceuticals Inc Stock

$49.63+0.50 (+1.02%)
Updated Feb 27, 2024
XENE Price
$49.63
Fair Value Price
-$0.59
Market Cap
$3.25B
52 Week Low
$27.99
52 Week High
$50.98
P/E
-18.73x
P/B
5.1x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$175.05M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.05
Operating Cash Flow
-$143M
Beta
0.82
Next Earnings
Feb 29, 2024
Ex-Dividend
N/A
Next Dividend
N/A

XENE Overview

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Zen Score

Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how XENE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

XENE ($49.63) is overvalued by 8,471.03% relative to our estimate of its Fair Value price of -$0.59 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
XENE ($49.63) is not significantly undervalued (8,471.03%) relative to our estimate of its Fair Value price of -$0.59 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
XENE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more XENE due diligence checks available for Premium users.

Be the first to know about important XENE news, forecast changes, insider trades & much more!

XENE News

Valuation

XENE fair value

Fair Value of XENE stock based on Discounted Cash Flow (DCF)
Price
$49.63
Fair Value
-$0.59
Undervalued by
8,471.03%
XENE ($49.63) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
XENE ($49.63) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
XENE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

XENE price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-18.73x
Industry
14.95x
Market
36.02x

XENE price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
5.1x
Industry
6.23x
XENE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

XENE's financial health

Profit margin

Revenue
$0.0
Net Income
-$48.5M
Profit Margin
0%
XENE's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$671.1M
Liabilities
$34.5M
Debt to equity
0.05
XENE's short-term assets ($531.01M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
XENE's short-term assets ($531.01M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
XENE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
XENE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$42.2M
Investing
$48.0M
Financing
$29.5M
XENE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

XENE vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
XENE$3.25B+1.02%-18.73x5.10x
DNA$3.24B+9.29%-3.64x2.59x
DNLI$3.23B+38.25%-25.11x2.89x
ARVN$3.27B-1.60%-7.25x4.95x
ACLX$3.29B+5.18%-25.52x12.37x

Xenon Pharmaceuticals Stock FAQ

What is Xenon Pharmaceuticals's quote symbol?

(NASDAQ: XENE) Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol XENE. Xenon Pharmaceuticals stock quotes can also be displayed as NASDAQ: XENE.

If you're new to stock investing, here's how to buy Xenon Pharmaceuticals stock.

What is the 52 week high and low for Xenon Pharmaceuticals (NASDAQ: XENE)?

(NASDAQ: XENE) Xenon Pharmaceuticals's 52-week high was $50.98, and its 52-week low was $27.99. It is currently -2.65% from its 52-week high and 77.35% from its 52-week low.

How much is Xenon Pharmaceuticals stock worth today?

(NASDAQ: XENE) Xenon Pharmaceuticals currently has 65,429,711 outstanding shares. With Xenon Pharmaceuticals stock trading at $49.63 per share, the total value of Xenon Pharmaceuticals stock (market capitalization) is $3.25B.

Xenon Pharmaceuticals stock was originally listed at a price of $10.50 in Nov 5, 2014. If you had invested in Xenon Pharmaceuticals stock at $10.50, your return over the last 9 years would have been 372.67%, for an annualized return of 18.84% (not including any dividends or dividend reinvestments).

How much is Xenon Pharmaceuticals's stock price per share?

(NASDAQ: XENE) Xenon Pharmaceuticals stock price per share is $49.63 today (as of Feb 27, 2024).

What is Xenon Pharmaceuticals's Market Cap?

(NASDAQ: XENE) Xenon Pharmaceuticals's market cap is $3.25B, as of Feb 29, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Xenon Pharmaceuticals's market cap is calculated by multiplying XENE's current stock price of $49.63 by XENE's total outstanding shares of 65,429,711.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.